Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651986 | 1.00 | BCL2 (0.86) | BCL2 | |
| SCHEMBL29376388 | 0.92 | BCL2 (0.82) | BCL2 | |
| SCHEMBL19839951 | 0.92 | BCL2 (0.82) | BCL2 | |
| SCHEMBL22858621 | 0.92 | BCL2 (0.85) | BCL2 | |
| SCHEMBL20580429 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL20580638 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL29652005 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL29651993 | 0.92 | BCL2 (0.86) | BCL2 | |
| SCHEMBL22858622 | 0.91 | BCL2 (0.86) | BCL2 | |
| SCHEMBL24520015 | 0.91 | BCL2 (0.72) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843751-B1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2024-03-27 | — | — | EP | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230149356-A1 | NOVEL MEDICAL USE OF MDM2 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| EP-4129999-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents Of The University Of Michigan (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3569601-B1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210002277-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-07 | — | — | US | disclosed |
| US-10829488-B2 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829488-B2 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3494115-B1 | N-(PHENYLSULFONYL)BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3569601-A2 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002277-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL2 2/4885 |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL3, BCL6 | BCL2 8/4885 |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | BCL2 43/4885 |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885 |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | BCL2 3/4885 |
| US-10829488-B2 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885 |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885 |
| US-20230149356-A1 | NOVEL MEDICAL USE OF MDM2 INHIBITORS | MDM2, TP53, TP53BP1 | BCL2 212/4885 |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | BCL2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.